Dr Rishabh Jain/X
Oct 17, 2026, 16:17
Rishabh Jain: Could Rusfertide Transform Polycythemia Vera Management?
Rishabh Jain, Medical Oncologist at AIIMS Delhi, shared a post on X:
“VERIFY Phase III | JCO 2026
Could rusfertide transform polycythemia vera management?
293 patients | Rusfertide vs placebo and SOC
- Clinical response: 77% vs 33% (P<0.0001)
- Phlebotomy-free: 73% vs 22%
- Sustained Hct <45%: 63% vs 14%
Fatigue and symptom scores improved.
Injection-site reactions and anemia; thrombosis reduction remains unproven.
Verdict: First-in-class hepcidin mimetic delivers a major advance in hematocrit control and phlebotomy reduction.
Longer-term clinical outcomes are needed.”
More posts featuring Rishabh Jain on Hemostasis Today.
-
Oct 17, 2026, 16:58Danny Hsu: Building Connections at the AUSNBled Collaborative Dinner in Auckland
-
Oct 17, 2026, 16:48Kalyan Roy: Enhancing Patient Experience Through Learning and Collaboration
-
Oct 17, 2026, 16:43Wilfried Dinh: Antiplatelet Therapy in 2026: Duration is Becoming a Dynamic Decision
-
Oct 17, 2026, 16:37Ian Setchfield: Dr. Evans Presents on Safe Anticoagulation Prescribing at East Kent Hospitals
-
Oct 17, 2026, 16:33Lewis Thomas: Connecting Through Shared Experiences at ASCAT 2026
-
Oct 17, 2026, 16:29Nilesh Jethwa: Yasmin Adverse Event Reports Exceed 23,000 Over Two-Year Period
-
Oct 17, 2026, 16:24W. Alberto Sifuentes Giraldo: Exploring Peripheral Macrovascular Thrombosis in CAPS
-
Oct 17, 2026, 16:16Fabrice Cognasse: Advancing Transfusion Medicine Through International Collaboration
-
Oct 17, 2026, 16:10Abdul Muqtadir Abbasi: PNH – How to Interpret Flow Cytometry